Innate Pharma S.A.
IPHYF
$1.50
$0.139.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.13M | 4.79M | 6.51M | 10.03M | 13.65M |
| Total Other Revenue | 7.02M | 7.10M | 7.22M | 7.59M | 8.11M |
| Total Revenue | 10.15M | 11.88M | 13.73M | 17.62M | 21.76M |
| Cost of Revenue | 49.39M | 48.15M | 47.24M | 51.24M | 56.23M |
| Gross Profit | -39.24M | -36.27M | -33.51M | -33.62M | -34.46M |
| SG&A Expenses | 21.91M | 21.71M | 21.65M | 21.27M | 21.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.30M | 69.86M | 68.89M | 72.51M | 77.56M |
| Operating Income | -61.15M | -57.98M | -55.16M | -54.89M | -55.79M |
| Income Before Tax | -55.81M | -52.78M | -50.09M | -51.31M | -53.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.81 | -52.78 | -50.09 | -51.31 | -53.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.81M | -52.78M | -50.09M | -51.31M | -53.52M |
| EBIT | -61.15M | -57.98M | -55.16M | -54.89M | -55.79M |
| EBITDA | -59.56M | -56.32M | -53.41M | -52.95M | -53.64M |
| EPS Basic | -0.62 | -0.61 | -0.60 | -0.62 | -0.66 |
| Normalized Basic EPS | -0.39 | -0.38 | -0.37 | -0.39 | -0.41 |
| EPS Diluted | -0.63 | -0.61 | -0.60 | -0.63 | -0.66 |
| Normalized Diluted EPS | -0.39 | -0.38 | -0.37 | -0.39 | -0.41 |
| Average Basic Shares Outstanding | 358.36M | 347.35M | 336.34M | 330.27M | 324.21M |
| Average Diluted Shares Outstanding | 358.36M | 347.35M | 336.34M | 330.27M | 324.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |